Significance of splenic vascular invasion in Hodgkin's disease

Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer.

Investigational new drugs·1998

Phase I trial of extracellular adenosine 5'-triphosphate in patients with advanced cancer.

Medical and pediatric oncology·1996

Clinical use of tumor markers in oncology.

Current problems in cancer·1991

Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?

Cancer·1989

Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index--Cancer.

Cancer·1988

Non-small cell lung cancer.

Disease-a-month : DM·1988

The 2026 report of the Lancet Countdown on health and climate change: a decade of escalating health harms and a decisive moment for all.

Lancet (London, England)·2026

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Lancet (London, England)·2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Lancet (London, England)·2026

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Lancet (London, England)·2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

BCL6 in B-cell lymphomas: old target, new tricks?

Haematologica·2026

[Application of"the layer of thymus-blood vessel-inferior parathyroid gland" in the in-situ preservation of the inferior parathyroid gland during central neck dissection of thyroid cancer: from anatomical study to surgical practice].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2026

Invasive Lobular Carcinoma With Extracellular Mucin Production: First Whole Exome Sequencing of a Rare Histological Variant of Breast Carcinoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026

A Mixed‑Valence Cu/Mn Bimetallic Coordination Polymer Nano‑Assembly Co‑Loaded With Taurine and Lenvatinib for Synergistic Tumor Chemo-Metalloimmunotherapy.

Advanced healthcare materials·2026

Machine learning, molecular docking, and experimental validation identify shared molecular signatures between idiopathic pulmonary arterial hypertension and malignant pleural mesothelioma: a retrospective study.

Frontiers in genetics·2026

Unusual [18F]FDOPA PET-CT maging of insulinomas in children.

EJNMMI reports·2026

Significance of splenic vascular invasion in Hodgkin's disease

Related Experiment Videos

Related Concept Videos

Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer.

Phase I trial of extracellular adenosine 5'-triphosphate in patients with advanced cancer.

Clinical use of tumor markers in oncology.

Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?

Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index--Cancer.

Non-small cell lung cancer.

The 2026 report of the Lancet Countdown on health and climate change: a decade of escalating health harms and a decisive moment for all.

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

BCL6 in B-cell lymphomas: old target, new tricks?

[Application of"the layer of thymus-blood vessel-inferior parathyroid gland" in the in-situ preservation of the inferior parathyroid gland during central neck dissection of thyroid cancer: from anatomical study to surgical practice].

Invasive Lobular Carcinoma With Extracellular Mucin Production: First Whole Exome Sequencing of a Rare Histological Variant of Breast Carcinoma.

A Mixed‑Valence Cu/Mn Bimetallic Coordination Polymer Nano‑Assembly Co‑Loaded With Taurine and Lenvatinib for Synergistic Tumor Chemo-Metalloimmunotherapy.

Machine learning, molecular docking, and experimental validation identify shared molecular signatures between idiopathic pulmonary arterial hypertension and malignant pleural mesothelioma: a retrospective study.

Unusual [18F]FDOPA PET-CT maging of insulinomas in children.

Significance of splenic vascular invasion in Hodgkin's disease

Related Experiment Videos

Related Concept Videos

Related Articles